Oncology Nursing Update with Dr Neil Love: Focus on Oncology Nursing

Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:
Introduction (00:00)
Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)
Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)
Utility of Belantamab Mafodotin in R/R MM (49:29)
Potential Role of Cereblon E3 Ligase Modulators in MM (1:07:01)

CME information and select publications

Featuring perspectives from Ms Kelly Fischer, Dr Marissa Marti-Smith, Dr Rita Nanda and Dr Ruth M O'Regan, moderated by Dr Nanda, including the following topics:
Introduction (00:00)
Advent of CDK4/6 Inhibitors in HR-Positive Breast Cancer (BC) (1:24)
Risk Assessment for Patients with HR-Positive, HER2-Negative Localized BC (2:52)
Adjuvant CDK4/6 Inhibitor Therapy (17:14)
Practical Considerations with CDK4/6 Inhibitors (29:57)
Monitoring and Management of Cytopenias (42:02)
CDK4/6 Inhibitors in HR-Positive Metastatic BC (49:32)
Management of Gastrointestinal Adverse Events (1:03:47)
CDK4/6 Inhibitors in Unique Populations (1:10:41)
Rarer CDK4/6 Inhibitor-Associated Toxicities (1:19:48)

CME information and select publications

Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics:
Introduction (00:00)
Overview of Ovarian Cancer (OC) (2:12)
Role of PARP Inhibitors in Advanced OC (4:56)
Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45)
Role of Relacorilant in Advanced OC (57:08)
Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12)

NCPD information and select publications

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:
Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)
Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)
Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)
Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43)
Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43)
Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15)
Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30)

CME information and select publications

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics:
Introduction (0:00)
Overview of Antibody-Drug Conjugates (ADCs) (2:07)
Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23)
Currently Available ADCs for Gynecologic Cancer Management (26:37)
Currently Available ADCs for Lung Cancer Management (44:07)
Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55)
Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07)
Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01)

NCPD information and select publications